Steve Lenier

J GORMAN MGMT

Articles

APL-2 slows growth of GA in phase II safety and efficacy trial

February 26, 2018

Twelve-month results of the FILLY trial show that in patients with geographic atrophy, the administration of complement C3 inhibitor APL-2 slowed the growth rate of the disease. It also appeared to increase the risk of new onset AMD, although this did not have an adverse effect on visual outcomes.